Home Administrative Billing & Reimbursement Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​​Important changes to Pepaxto® coverage

December 6, 2021

​The manufacturer of Pepaxto® (melphalan flufenamide) has removed the drug from the market due to safety concerns. Based on this decision, AmeriHealth will archive Medical Policy #08.01.78b: Melphalan flufenamide (Pepaxto®) as of January 1, 2022.

HCPCS code J9247 Injection, melphalan flufenamide, 1mg, will be set up as Experimental/Investigational and included in our Experimental/Investigational Services policy #12.01.01.

You can read about the decision on our Medical and Claim Payment Policy Portal or on the manufacturer's website.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of AmeriHealth, AmeriHealth HMO, Inc., AmeriHealth Insurance Company of New Jersey.
© 2023 AmeriHealth Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer